Rituximab Treatment and Monitoring in Pemphigus Vulgaris
Introduction to Rituximab Protocol
- The British Journal of Dermatology recommends a pemphigus-specific protocol that achieves 89% complete remission off all treatment at 2 years when combined with short-term prednisolone 1, 2, 3
Platelet Count Monitoring
- There are no established platelet count thresholds for initiating or continuing rituximab in pemphigus vulgaris patients, as stated by the British Journal of Dermatology 1
- Late-onset neutropenia, not thrombocytopenia, is the primary hematologic concern with rituximab, occurring more commonly when combined with chemotherapy, according to Blood 6, 7
Clinical Response and Relapse
- Initial improvement is expected within 6 weeks of administration, with complete healing averaging 15 weeks, and disease control lasting a mean of 11 months, as reported by the British Journal of Dermatology 1, 3
- Relapse is expected in 40-65% of patients, typically occurring 13-17 months after rituximab, with an average remission duration of 58 months, according to the British Journal of Dermatology 1, 2, 3
Infection Prophylaxis and Safety Considerations
- The American Journal of Hematology suggests that PCP prophylaxis should be considered during and following rituximab treatment, particularly with triple immunosuppression or additional risk factors 5
- Screening for hepatitis B is necessary before initiating rituximab, as reactivation can be fatal, as recommended by Praxis Medical Insights 2
- Rituximab carries risks of severe mucocutaneous reactions, hepatitis B reactivation, and progressive multifocal leukoencephalopathy, with a 3% death rate in uncontrolled trials for ITP, according to the American Journal of Hematology 5